OncRef

Clinical Trial: NCT03703167

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-01-29

Study Overview

Brief Summary

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Official Title

Phase Ib Trial With Dose Expansion of the Bruton"s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Conditions

Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)

Intervention / Treatment

  • Drug: Ibrutinib
  • Drug: Lenalidomide
  • Drug: Rituximab

Other Study ID Numbers

  • 18-432

Start Date (Actual)

2019-01-22

Primary Completion Date (Actual)

2026-01-26

Study Completion Date (Actual)

2026-01-26

Enrollment (Actual)

25

Study Type

Interventional

Phase

Phase 1